Similar articles

• Does a BRCA mutation plus tamoxifen equal hysterectomy?

  Lu KH, Kauff ND. Lu KH, et al. Gynecol Oncol. 2007 Jan;104(1):3-4. doi: 10.1016/j.ygyno.2006.11.015. Gynecol Oncol. 2007. PMID: 17222708 No abstract available.
• [Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen].

  Doridot V, This P, Clough KB. Doridot V, et al. J Gynecol Obstet Biol Reprod (Paris). 2002 Nov;31(7):677-80. J Gynecol Obstet Biol Reprod (Paris). 2002. PMID: 12457141 French.
• Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

  Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Kauff ND, et al. N Engl J Med. 2002 May 23;346(21):1609-15. doi: 10.1056/NEJMoa020119. Epub 2002 May 20. N Engl J Med. 2002. PMID: 12023992
• Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

  Kauff ND, Barakat RR. Kauff ND, et al. J Clin Oncol. 2007 Jul 10;25(20):2921-7. doi: 10.1200/JCO.2007.11.3449. J Clin Oncol. 2007. PMID: 17617523 Review.
• The role of ovarian ablation in the management of breast cancer.

  Wirk B. Wirk B. Breast J. 2005 Nov-Dec;11(6):416-24. doi: 10.1111/j.1075-122X.2005.00122.x. Breast J. 2005. PMID: 16297086 Review.